What Is Trigeminal Neuralgia?
The trigeminal nerve is the fifth cranial nerve, which carries sensation from the face. In trigeminal neuralgia there are very brief but very severe attacks of pain along this nerve, most often around the cheek, jaw or eye. The pain is frequently triggered by ordinary stimuli such as chewing, talking, brushing the teeth, wind or touching the face. The most common cause is a blood vessel pressing on the trigeminal nerve at its exit from the brainstem (classic trigeminal neuralgia); less often there are secondary causes such as multiple sclerosis or a tumor. For this reason a detailed neurological examination and thin-slice MRI are important in diagnosis; MRI can both show the vascular compression and rule out secondary causes.
First Step: Medical Treatment
The first step in trigeminal neuralgia treatment — and the only step needed in many patients — is medication. Certain antiseizure drugs such as carbamazepine and oxcarbazepine are highly effective for this pain and control it in a substantial proportion of patients. Treatment is started at a low dose and adjusted according to effect and side effects. For this reason not every patient with facial pain is a direct surgical candidate; surgery is considered only when even an adequate dose of medication fails to control the pain, or when the patient cannot tolerate the side effects (drowsiness, unsteadiness, changes in blood values). A response of the pain to medication is also regarded as a finding that supports the diagnosis of classic trigeminal neuralgia.
Surgical Options
In drug-resistant cases there are three main approaches. Microvascular decompression (MVD) is the only method that aims to remove the cause: through a small craniotomy behind the ear, the vessel compressing the nerve is found under the microscope and a soft cushion is placed between nerve and vessel to relieve the compression; the chance of long-term pain freedom is high, especially in younger patients in good general condition with clear vascular compression on MRI. The second group consists of percutaneous (needle-based) procedures that reduce pain transmission by causing controlled damage to the nerve (balloon compression, glycerol injection, radiofrequency); these are less invasive and suitable for older patients or those with comorbidities, but carry a risk of facial numbness and recurrence. The third option is radiosurgery (Gamma Knife); it is preferred in patients unsuitable for surgery, and its effect begins over weeks.
Assessment and Recovery
The process begins with a detailed pain history, neurological examination and a thin-slice MRI dedicated to the trigeminal nerve; the MRI both assesses vascular compression and rules out secondary causes such as multiple sclerosis or a tumor. If pain persists after medication has been optimised, the surgical options are evaluated together with the patient. Microvascular decompression is performed under general anaesthesia and takes a few hours; it is usually followed by a short period of intensive care and a hospital stay of a few days. Percutaneous procedures are mostly shorter and allow faster discharge. Which method is chosen is decided together according to the patient's age, general health, MRI findings and preference.
Risks and Realistic Expectations
Each method has its own risks, and these must be discussed honestly. Microvascular decompression is major surgery; though rare, it carries risks of hearing loss, facial weakness, cerebrospinal fluid leak and the general risks of surgery, but it offers the highest chance of pain freedom with the lowest risk of facial numbness. Percutaneous procedures are less invasive but carry a higher probability of permanent facial numbness and recurrence. Gamma Knife is painless but its effect begins with a delay and may diminish over time. No method guarantees lifelong pain freedom; recurrence is possible with every method. The most suitable option for you and a realistic expectation of success are shared openly before surgery based on your findings.